Clostridium difficile is commonly the agent responsible for antibiotic associated diarrhoea, colitis, and pseudomembranous colitis in humans.'2 The antibiotic depresses the bacterial flora which normally counteract extended colonisation by C difficile in the gut. 34 The pathogenic effects of C difficile are probably mediated by exotoxins, the two most important being toxin A and toxin B.`6 Toxin A is an enterotoxin, responsible for haemorrhagic fluid accumulation in intestinal loops of rats, rabbits, and hamsters.7`' Toxin A also causes elongation of ovary cells in Chinese hamsters, an effect similar to that of enterotoxins from Vibrio cholerae, Escherichia coli, and Campylobacter jejuni. "' Toxin B induces intestinal secretion without any apparent damage to the intestinal mucosa. " Colonisation with C difficile toxigenic strains during treatment with antibiotics might occur, however, without any clinical sign of intestinal disease. Intestinal resistance to this pathological challenge is probably mediated by a variety of defence mechanisms, including those triggered by immunocomponent cells. Recently, a new protein was reported which counteracts the in vivo secretory action of the enterotoxins from V cholerae, E coli, and Cjejuni.`This protein was designated antisecretory factor, owing to its capacity to inhibit intestinal fluid secretion. It is mainly synthesised in the central nervous system and is secreted from the pituitary gland into the blood, milk, and bile. '6 In young animals there is normally no production ofantisecretory factor, but after intestinal challenge with enterotoxin production is induced in the central nervous system. Antisecretory factor from pigs consists of one peptide chain with a molecular mass of 60 kDa. 7 It attaches with high affinity to galactosecontaining polysaccharides such as agarose, but is dissociated again by elution with galactose or methyl a-D-glucoside.
In contrast to the enterotoxins from V cholerae and E coli, toxin A from C difficile causes intestinal hypersecretion in combination with extensive destruction of the mucosa. It was therefore important to investigate whether this toxin induced a similar formation of antisecretory factor as that induced after hypersecretion caused by the non-tissue damaging enterotoxins. The antisecretory factor activity present in the pituitary gland was purified and characterised. Preliminary electrofocusing using ampholine pH 3.5-10 showed that the activity focused between pH 5.0 and 6.0. Ampholine pH 4-6 was then used for better resolution. In this gradient the activity focused in two peaks, one corresponding to pI 5 0 and the other to pI 5-4 (Fig 1) . The fraction pI 5-4 inhibited toxin A and cholera toxin-induced secretion, while the fraction pI 5 0 counteracted secretion induced by toxin A but not that induced by cholera toxin (Table I) . Antiserum against porcine antisecretory factor abolished the activity of fraction pI 5.4, but not that of fraction pI 5.0 (Table I) . Both fractions attached to agarose gel with high affinity and dissociated again in a gradient of methyl a-Dglucoside. Antisecretory factor of pl 5.0, however, dissociated with a 0 1 M concentration of the sugar, while that of pI 5.4 mainly dissociated at a concentration of 0-9-1 .5 M (Table II) . The pI 5.0 fraction (specific for toxin A) was further characterised. It was run in sodium dodecylsulphate-polyacrylamide gel electrophoresis to estimate its molecular size. The antisecretory activity migrated in two peaks, the main peak corresponding to an approximate molecular size of 60 kDa and the minor peak to about 30 kDa compared with the migration of the protein markers (Fig 2) .
Methods

MORPHOLOGY
Immunohistochemistry was used to study binding oftoxin A to the mucosa ofthe small intestine in loops challenged with toxin for 60 minutes. In control animals not treated with antisecretory factor, binding of toxin A could be shown in the microvilli region of enterocytes on the villi ( Fig  3A) . No binding of the toxin to epithelial cells in the crypts was evident. Treatment of the animals with antisecretory factor did not affect the binding of the toxin to the mucosa, since a binding pattern similar to the control was seen (Fig 3B) . Six hours after injection of toxin A extensive damage to the mucosa was seen in control animals ( Fig 3C) . In contrast, in rats treated with antisecretory factor the mucosa was well protected from the destructive effects oftoxin A ( Fig  3D) . In these protected animals some shedding of epithelial cells from the upper parts of the villi was observed, but otherwise the morphology was fairly well preserved. There was no evidence of haemorrhage in the intestinal wall.
Discussion
The formation ofantisecretory factor in rats after a challenge with cholera toxin has been clearly shown.'3`7 The results from previous studies implied that antisecretory factor was released as a response to the hypersecretion rather than as a response to the causative toxin. In contrast to these non-tissue damaging enterotoxins, toxin A from C difficile induces two kinds ofantisecretory factor in the pituitary gland of rats, one of pI 5.4 and one of pI 50.
Antisecretory factor with a pI of 5.4 inhibited fluid secretion in the small intestine, both that induced by cholera toxin and that induced by toxin A. The activity seemed to be similar to that of pig antisecretory factor which inhibits the secretory effects of several different enterotoxins.'4 An antisecretory factor ofpI 5 4 was also neutralised by antiserum against porcine antisecretory factor, which suggests that these two proteins are antigenically related. An antisecretory factor of pI 5-0, however, differed from the antisecretory factor proteins previously described; it did not reverse cholera toxin induced secretion, but had a pronounced inhibitory effect on toxin A induced secretion. These results suggest that an antisecretory factor of pl 5- Immunity to C difficile disease through vaccines has proved difficult to induce.2324 The newly discovered antisecretory factor proteins seem to be a promising alternative for the control of diarrhoeal diseases. Moreover, the present results suggest that these proteins have a potential capacity to control toxin induced tissue damaging intestinal disorders. 
